Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (април 2011). „New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats”. Pharmacology, Biochemistry, and Behavior. 98 (2): 227—33. PMID21215770. S2CID24650035. doi:10.1016/j.pbb.2010.12.019.CS1 одржавање: Формат датума (веза)
Abiero A, Botanas CJ, Custodio RJ, Sayson LV, Kim M, Lee HJ, et al. (март 2020). „4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels”. Psychopharmacology. 237 (3): 757—772. PMID31828394. S2CID209169410. doi:10.1007/s00213-019-05412-y.CS1 одржавање: Формат датума (веза)
Colestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, et al. (фебруар 2018). „Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues”. Drug Testing and Analysis. 10 (2): 272—283. PMID28513099. doi:10.1002/dta.2213.CS1 одржавање: Формат датума (веза)
Mitsuoka T, Hanamura K, Koganezawa N, Kikura-Hanajiri R, Sekino Y, Shirao T (2019). „Assessment of NMDA receptor inhibition of phencyclidine analogues using a high-throughput drebrin immunocytochemical assay”. Journal of Pharmacological and Toxicological Methods. 99: 106583. PMID31082488. doi:10.1016/j.vascn.2019.106583.
nih.gov
ncbi.nlm.nih.gov
Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (април 2011). „New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats”. Pharmacology, Biochemistry, and Behavior. 98 (2): 227—33. PMID21215770. S2CID24650035. doi:10.1016/j.pbb.2010.12.019.CS1 одржавање: Формат датума (веза)
Abiero A, Botanas CJ, Custodio RJ, Sayson LV, Kim M, Lee HJ, et al. (март 2020). „4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels”. Psychopharmacology. 237 (3): 757—772. PMID31828394. S2CID209169410. doi:10.1007/s00213-019-05412-y.CS1 одржавање: Формат датума (веза)
Colestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, et al. (фебруар 2018). „Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues”. Drug Testing and Analysis. 10 (2): 272—283. PMID28513099. doi:10.1002/dta.2213.CS1 одржавање: Формат датума (веза)
Mitsuoka T, Hanamura K, Koganezawa N, Kikura-Hanajiri R, Sekino Y, Shirao T (2019). „Assessment of NMDA receptor inhibition of phencyclidine analogues using a high-throughput drebrin immunocytochemical assay”. Journal of Pharmacological and Toxicological Methods. 99: 106583. PMID31082488. doi:10.1016/j.vascn.2019.106583.
nsddb.eu
„3-MeO-PCMo”. New Synthetic Drugs Database. Архивирано из оригинала 2016-07-03. г. Приступљено 2016-02-09.
semanticscholar.org
api.semanticscholar.org
Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (април 2011). „New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats”. Pharmacology, Biochemistry, and Behavior. 98 (2): 227—33. PMID21215770. S2CID24650035. doi:10.1016/j.pbb.2010.12.019.CS1 одржавање: Формат датума (веза)
Abiero A, Botanas CJ, Custodio RJ, Sayson LV, Kim M, Lee HJ, et al. (март 2020). „4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels”. Psychopharmacology. 237 (3): 757—772. PMID31828394. S2CID209169410. doi:10.1007/s00213-019-05412-y.CS1 одржавање: Формат датума (веза)
web.archive.org
„3-MeO-PCMo”. New Synthetic Drugs Database. Архивирано из оригинала 2016-07-03. г. Приступљено 2016-02-09.